San Francisco startup Framework Therapeutics is also focusing on an oral, once-everyday GLP-1 drug known as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June each time a mid-stage research showed regular weight loss of all around 6% and it options to start out Yet another mid-phase trial towards the top of the yr—that founder a